MedPath

The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories

Not Applicable
Active, not recruiting
Conditions
Intrusive Memories
Interventions
Drug: Placebo
Registration Number
NCT04871269
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

The aim of the current project is to investigate the impact of an activation of the cannabinoid system with an exogenous cannabinoid dronabinol (delta-9-tetrahydrocannabinol) on the formation of intrusive memories after analog trauma.

A well-established stress-film paradigm will be used to induce intrusive symptoms in healthy participants. In a double-blind placebo-controlled study, the impact of exogenous dronabinol on intrusive symptoms during exposure to a trauma film will be examined. The primary hypothesis is that exogenous oral dronabinol will decrease the number of intrusive memories recorded in the four days following experimental trauma compared with placebo controls.

This project will contribute to the current understanding of intrusive memory formation in PTSD and may guide the development of future pharmacological preventions.

Detailed Description

Recent data suggest that the cannabinoid-system is involved in stress regulation and posttraumatic stress disorder (PTSD) after traumatic events. In own of our own studies, we found reduced concentrations of the endocannabinoid arachidonylethanolamide (AEA) in BPD patients compared to healthy women (see Fig 1a). Furthermore, we found a correlation between hair concentrations of AEA and cortisol (p = .06; Fig 1b).

Low endocannabinoid signaling has been found in PTSD patients and might even present a precondition to develop PTSD after trauma. In consequence, increased endocannabinoid signaling during acquisition and consolidation of traumatic events might be a promising approach to prevent the development of PTSD. The aim of the current project is to investigate the impact of an activation of the cannabinoid system with an exogenous cannabinoid dronabinol (delta-9-tetrahydrocannabinol) on the formation of intrusive memories after analog trauma.

A well-established stress-film paradigm will be used to induce intrusive symptoms in healthy participants. In a double-blind placebo-controlled study, the impact of exogenous dronabinol on intrusive symptoms during exposure to a trauma film will be examined. The primary hypothesis is that exogenous oral dronabinol will decrease the number of intrusive memories recorded in the four days following experimental trauma compared with placebo controls.

This project will contribute to the current understanding of intrusive memory formation in PTSD and may guide the development of future pharmacological preventions.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
291
Inclusion Criteria
  • healthy female volunteers
  • German on a native level
Exclusion Criteria
  • former or present disorder according to the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5)
  • any physical illnesses
  • any medication intake (except oral contraceptive)
  • history of traumatic experience, e.g. history of sexual abuse or rape
  • pregnancy or lactation period
  • follicular phase of menstrual cycle for all women not using oral contraceptives

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Drug: Dronabinol before the trauma film paradigmPlacebo-
Drug: Dronabinol after the trauma film paradigmPlacebo-
Placebo before and after the trauma film paradigmPlacebo-
Drug: Dronabinol before the trauma film paradigmDronabinol-
Drug: Dronabinol after the trauma film paradigmDronabinol-
Primary Outcome Measures
NameTimeMethod
Change of Intrusive Memories in the following four days after the interventionfour consecutive days

Influence of dronabinol on the development of intrusive memories measured with an intrusion diary

Secondary Outcome Measures
NameTimeMethod
Noradrenergic System (measured with salivary alpha-amylase - u/ml)Day 1

Influence of dronabinol on the noradrenergic system measured with salivary alpha-amylase

Hypothalamic-pituitary-adrenal (HPA) axis (measured with salivary cortisol - nmol/L)Time Frame: Day 1

Influence of dronabinol on the HPA-axis measured with salivary cortisol

Polygenic Risk Score Influence of polygenic risk score on development of intrusive memoriesDay 1

Influence of polygenic risk score on development of intrusive memories

Trial Locations

Locations (1)

Charité - Universitätsmedizin Berlin

🇩🇪

Berlin-Steglitz, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath